XML 55 R40.htm IDEA: XBRL DOCUMENT v3.25.0.1
Segment Reporting (Tables)
12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Schedule of Breakdown of Significant Operating Expenses

 

   2024   2023 
   Year ended December 31, 
   2024   2023 
Revenue  $582   $68 
Cost of revenues   96    236 
Gross profit (loss)   486    (168)
Operating expenses:          
Research and development by significant expense:          
MSA/license fees   3,017    3,250 
Professional fees   759    1,181 
Payroll and related   502    701 
Other1   326    788 
Research and development   4,604    5,920 
General and administrative by significant expense:          
Occupancy expense   5,074    3,306 
Professional fees   4,168    6,464 
Payroll and related   1,607    2,045 
Stock-based compensation   1,431    1,008 
Other2   852    1,764 
General and administrative   13,132    14,587 
Gain on lease termination   (1,576)   - 
Acquisition of Exacis in-process research and development   -    460 
Total operating expenses   16,160    20,967 
Loss from operations   (15,674)   (21,135)
Other expense, net   (28,835)   (536)
Loss before income taxes   (44,509)   (21,671)
(Provision) benefit for income taxes   (30)   3 
Net loss  $(44,539)  $(21,668)
Cash  $1,729   $7,575 

 

1Other includes certain lab supply expenses, amounts related to the close out of a former clinical trial, allocated occupancy costs, stock-based compensation, and depreciation.

 

2Other includes expenses related to insurance, information technology, travel, banking, depreciation and other miscellaneous expenses.